Background: (rearranged during transfection) variants are the most prevalent oncogenic events in medullary thyroid cancer (MTC). In advanced disease, multi-tyrosine kinase inhibitors (MKIs) cabozantinib and vandetanib are the approved standard treatment irrespective of status. The actual outcome of patients with -positive MTC treated with MKIs is ill described.
Methods: We here retrospectively determined the oncogene variant status with a targeted DNA Custom Panel in a prospectively collected cohort of 48 patients with advanced MTC treated with vandetanib and/or cabozantinib at four German referral centers. Progression-free survival (PFS) and overall survival (OS) probabilities were estimated using the Kaplan-Meier method.
Results: In total, 44/48 (92%) patients had germline or somatic variants. The M918T variant was found in 29/44 (66%) cases. In total, 2/32 (6%) patients with a somatic variant had further somatic variants, while in 1/32 (3%) patient with a germline variant, additional variants were found. Only 1/48 (2%) patient had a pathogenic variant, and no variants were found in 3 cases. In first-line treatment, the median OS was 53 (95% CI (95% confidence interval), 32-NR (not reached); = 36), and the median PFS was 21 months (12-39; = 33) in -positive MTC patients. In second-line treatment, the median OS was 18 (13-79; = 22), and the median PFS was 3.5 months (2-14; = 22) in -positive cases.
Conclusions: variants were highly prevalent in patients with advanced MTC. The treatment results in -positive cases were similar to those reported in unselected cohorts.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324961 | PMC |
http://dx.doi.org/10.3390/cancers14143405 | DOI Listing |
Endokrynol Pol
January 2025
Department of Paediatric Oncology, The Children's Memorial Health Institute, Warsaw, Poland.
The rapid progress made in recent years in thyroid cancer research has necessitated the systematic updating of current clinical recommendations. This update presents the evidence-based management of differentiated thyroid carcinoma (DTC) and medullary thyroid carcinoma in children, including preoperative diagnostics, surgical management, radioiodine therapy in DTC treatment with L-thyroxine, disease monitoring, treatment of advanced disease, and finally, consequences of thyroid cancer treatment. Each recommendation is evaluated regarding its strength (Strength of Recommendation; SoR) and the quality of supporting data (QoE - Quality of Evidence).
View Article and Find Full Text PDFOral Oncol
January 2025
School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China; Department of Otolaryngology Head and Neck Surgery, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing 210019, Jiangsu, China. Electronic address:
World J Surg Oncol
January 2025
Department of Thoracic Surgery, University Hospitals Birmingham, Birmingham, UK.
A 34-year-old male patient with recently diagnosed with medullary thyroid carcinoma underwent total thyroidectomy and radical neck dissection, requiring sharp dissection to separate the tumour from the trachea. He required post operative intubation due to bilateral vocal cord paralysis. He developed ischaemic necrosis of the upper two thirds of the trachea presenting with marked surgical emphysema and an infective wound.
View Article and Find Full Text PDFJ Nucl Med
January 2025
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
Several exploratory studies have demonstrated the feasibility of cholecystokinin-2 receptor (CCK2R) targeting in patients with medullary thyroid carcinoma (MTC) and other neuroendocrine tumors (NETs). We report the results of a prospective phase I/IIA pilot study (clinicaltrials.gov NCT06155994) conducted at our center with the Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH (Ga-DOTA-MGS5).
View Article and Find Full Text PDFJ Clin Transl Endocrinol
March 2025
Department of Ultrasound, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, PR China.
Objectives: This study aimed to evaluate the diagnostic performance for medullary thyroid cancer (MTC) based on the 2017 Thyroid Imaging Reporting and Data System by the American College of Radiology (ACR TI-RADS) guideline, and the ability to recommend fine needle aspiration (FNA) for MTC.
Methods: Fifty-six MTCs were included, and 168 benign thyroid nodules (BTNs) and 168 papillary thyroid nodules (PTCs) were matched according to age. Ultrasound (US) features were reviewed according to ACR TI-RADS.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!